Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

HIGHLIGHTS

• who: Ying Jiang from the Kline InstituteTs, (Stock No., ) mice, and wild type breeding partner (B EiC SnF1/J, Stock No., ) from the same colony were obtained from The Jackson Laboratory (Bar Harbor, ME). The protocol for drug dosage and oral gavage procedure was approved by the IACUC committee of Nathan S. Kline Institute (NKI) and renewed every three years, with the current protocol number AP2021-685-NKI. The test compound neflamapimod (manufacturer lot number, ) and instructions for formulation preparation, route of administration and dosing volume were provided by EIP Pharma, Inc. Both wild-type (, N) and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.